Skip to main content

View full-text article in PMC

. 2011 Jun;71(6):852–859. doi: 10.1111/j.1365-2125.2011.03914.x

Table 3.

Free tissue : total plasma availability ratios

Treatment	AUC_{tissue i.m.}: AUC_plasma	AUC_{tissue s.c.} : AUC_plasma
Test A: DCF100C1 (1%)	0.14 ± 0.24 (range 0.01–0.72; n = 8)	0.10 ± 0.13 (range 0.01–0.47; n = 10)
Test B: DCF100C2 (1%)	0.12 ± 0.05 (range 0.03–0.21; n = 12)	0.13 ± 0.12 (range 0.02–0.37; n = 11)
Test C: DCF100C1 (2.5%)	0.04 ± 0.04 (range 0.01–0.12; n = 11)	0.05 ± 0.04 (range 0.01–0.12; n = 11)
Test D: DCF100C2 (2.5%)	0.85 ± 2.62 (range 0–8.76; n = 11)	0.16 ± 0.22 (range 0.01–0.79; n = 11)
Test E: Voltaren® Emulgel®	0.62 ± 1.11 (range 0.02–3.36; n = 10)	0.73 ± 1.33 (range 0.06–4.66; n = 11)

Results are given as means ± SD (range).